Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
69
SDMHF Quote, Financials, Valuation and Earnings
Last price:
$247.25
Seasonality move
:
2.68%
Day range:
$247.25 - $247.25
52-week range:
$170.00 - $248.55
Dividend yield:
0.3%
P/E ratio:
82.54x
P/S ratio:
7.39x
P/B ratio:
5.07x
Volume:
--
Avg. volume:
3.6K
1-year change:
40.4%
Market cap:
$24.1B
Revenue:
$3B
EPS (TTM):
$3.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SDMHF
Sartorius Stedim Biotech SA
|
-- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$9.6M | -$0.10 | -5.7% | -56.58% | $7.20 |
|
DBVT
DBV Technologies SA
|
$889.9K | -$0.34 | -- | -77.25% | $20.57 |
|
IPHA
Innate Pharma SA
|
$2.3M | -- | -- | -- | $5.15 |
|
IVA
Inventiva SA
|
$10.1M | -$0.29 | -- | -- | $15.33 |
|
NBTX
Nanobiotix SA
|
-- | -- | -- | -- | $14.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SDMHF
Sartorius Stedim Biotech SA
|
$247.25 | -- | $24.1B | 82.54x | $0.74 | 0.3% | 7.39x |
|
CLLS
Cellectis SA
|
$4.74 | $7.20 | $475.5M | -- | $0.00 | 0% | 5.90x |
|
DBVT
DBV Technologies SA
|
$13.90 | $20.57 | $380.3M | -- | $0.00 | 0% | -- |
|
IPHA
Innate Pharma SA
|
$1.89 | $5.15 | $174.2M | -- | $0.00 | 0% | 24.41x |
|
IVA
Inventiva SA
|
$4.13 | $15.33 | $602.4M | -- | $0.00 | 0% | 24.04x |
|
NBTX
Nanobiotix SA
|
$21.15 | $14.75 | $1B | -- | $0.00 | 0% | 29.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SDMHF
Sartorius Stedim Biotech SA
|
38.84% | 0.092 | 15.64% | 0.40x |
|
CLLS
Cellectis SA
|
54.27% | 0.665 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -1.892 | 5.85% | 1.41x |
|
IPHA
Innate Pharma SA
|
55.22% | -1.046 | -- | 2.76x |
|
IVA
Inventiva SA
|
-145.15% | -0.179 | 32.05% | 0.43x |
|
NBTX
Nanobiotix SA
|
195.9% | 4.777 | 20.12% | 1.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SDMHF
Sartorius Stedim Biotech SA
|
$382.6M | $163.2M | 3.83% | 6.53% | 19.8% | -$83.8M |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
IPHA
Innate Pharma SA
|
-- | -- | -39.78% | -72.79% | -- | -- |
|
IVA
Inventiva SA
|
-- | -- | -- | -- | -- | -- |
|
NBTX
Nanobiotix SA
|
-- | -- | -161.14% | -- | -- | -- |
Sartorius Stedim Biotech SA vs. Competitors
-
Which has Higher Returns SDMHF or CLLS?
Cellectis SA has a net margin of 9.17% compared to Sartorius Stedim Biotech SA's net margin of 1.68%. Sartorius Stedim Biotech SA's return on equity of 6.53% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital SDMHFSartorius Stedim Biotech SA46.39% $0.77 $7.8B CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About SDMHF or CLLS?
Sartorius Stedim Biotech SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 51.9%. Given that Cellectis SA has higher upside potential than Sartorius Stedim Biotech SA, analysts believe Cellectis SA is more attractive than Sartorius Stedim Biotech SA.
Company Buy Ratings Hold Ratings Sell Ratings SDMHFSartorius Stedim Biotech SA0 0 0 CLLSCellectis SA2 2 0 -
Is SDMHF or CLLS More Risky?
Sartorius Stedim Biotech SA has a beta of 1.105, which suggesting that the stock is 10.462% more volatile than S&P 500. In comparison Cellectis SA has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.784%.
-
Which is a Better Dividend Stock SDMHF or CLLS?
Sartorius Stedim Biotech SA has a quarterly dividend of $0.74 per share corresponding to a yield of 0.3%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius Stedim Biotech SA pays 38.14% of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend. Sartorius Stedim Biotech SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SDMHF or CLLS?
Sartorius Stedim Biotech SA quarterly revenues are $824.6M, which are larger than Cellectis SA quarterly revenues of $35M. Sartorius Stedim Biotech SA's net income of $75.6M is higher than Cellectis SA's net income of $586.4K. Notably, Sartorius Stedim Biotech SA's price-to-earnings ratio is 82.54x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius Stedim Biotech SA is 7.39x versus 5.90x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDMHFSartorius Stedim Biotech SA7.39x 82.54x $824.6M $75.6M CLLSCellectis SA5.90x -- $35M $586.4K
-
Which has Higher Returns SDMHF or DBVT?
DBV Technologies SA has a net margin of 9.17% compared to Sartorius Stedim Biotech SA's net margin of --. Sartorius Stedim Biotech SA's return on equity of 6.53% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital SDMHFSartorius Stedim Biotech SA46.39% $0.77 $7.8B DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About SDMHF or DBVT?
Sartorius Stedim Biotech SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $20.57 which suggests that it could grow by 47.98%. Given that DBV Technologies SA has higher upside potential than Sartorius Stedim Biotech SA, analysts believe DBV Technologies SA is more attractive than Sartorius Stedim Biotech SA.
Company Buy Ratings Hold Ratings Sell Ratings SDMHFSartorius Stedim Biotech SA0 0 0 DBVTDBV Technologies SA3 0 1 -
Is SDMHF or DBVT More Risky?
Sartorius Stedim Biotech SA has a beta of 1.105, which suggesting that the stock is 10.462% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.
-
Which is a Better Dividend Stock SDMHF or DBVT?
Sartorius Stedim Biotech SA has a quarterly dividend of $0.74 per share corresponding to a yield of 0.3%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius Stedim Biotech SA pays 38.14% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Sartorius Stedim Biotech SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SDMHF or DBVT?
Sartorius Stedim Biotech SA quarterly revenues are $824.6M, which are larger than DBV Technologies SA quarterly revenues of --. Sartorius Stedim Biotech SA's net income of $75.6M is higher than DBV Technologies SA's net income of -$33M. Notably, Sartorius Stedim Biotech SA's price-to-earnings ratio is 82.54x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius Stedim Biotech SA is 7.39x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDMHFSartorius Stedim Biotech SA7.39x 82.54x $824.6M $75.6M DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns SDMHF or IPHA?
Innate Pharma SA has a net margin of 9.17% compared to Sartorius Stedim Biotech SA's net margin of --. Sartorius Stedim Biotech SA's return on equity of 6.53% beat Innate Pharma SA's return on equity of -72.79%.
Company Gross Margin Earnings Per Share Invested Capital SDMHFSartorius Stedim Biotech SA46.39% $0.77 $7.8B IPHAInnate Pharma SA-- -- $68.9M -
What do Analysts Say About SDMHF or IPHA?
Sartorius Stedim Biotech SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 172.7%. Given that Innate Pharma SA has higher upside potential than Sartorius Stedim Biotech SA, analysts believe Innate Pharma SA is more attractive than Sartorius Stedim Biotech SA.
Company Buy Ratings Hold Ratings Sell Ratings SDMHFSartorius Stedim Biotech SA0 0 0 IPHAInnate Pharma SA3 2 0 -
Is SDMHF or IPHA More Risky?
Sartorius Stedim Biotech SA has a beta of 1.105, which suggesting that the stock is 10.462% more volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.
-
Which is a Better Dividend Stock SDMHF or IPHA?
Sartorius Stedim Biotech SA has a quarterly dividend of $0.74 per share corresponding to a yield of 0.3%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius Stedim Biotech SA pays 38.14% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Sartorius Stedim Biotech SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SDMHF or IPHA?
Sartorius Stedim Biotech SA quarterly revenues are $824.6M, which are larger than Innate Pharma SA quarterly revenues of --. Sartorius Stedim Biotech SA's net income of $75.6M is higher than Innate Pharma SA's net income of --. Notably, Sartorius Stedim Biotech SA's price-to-earnings ratio is 82.54x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius Stedim Biotech SA is 7.39x versus 24.41x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDMHFSartorius Stedim Biotech SA7.39x 82.54x $824.6M $75.6M IPHAInnate Pharma SA24.41x -- -- --
-
Which has Higher Returns SDMHF or IVA?
Inventiva SA has a net margin of 9.17% compared to Sartorius Stedim Biotech SA's net margin of --. Sartorius Stedim Biotech SA's return on equity of 6.53% beat Inventiva SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SDMHFSartorius Stedim Biotech SA46.39% $0.77 $7.8B IVAInventiva SA-- -- -$34.6M -
What do Analysts Say About SDMHF or IVA?
Sartorius Stedim Biotech SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 271.27%. Given that Inventiva SA has higher upside potential than Sartorius Stedim Biotech SA, analysts believe Inventiva SA is more attractive than Sartorius Stedim Biotech SA.
Company Buy Ratings Hold Ratings Sell Ratings SDMHFSartorius Stedim Biotech SA0 0 0 IVAInventiva SA8 0 0 -
Is SDMHF or IVA More Risky?
Sartorius Stedim Biotech SA has a beta of 1.105, which suggesting that the stock is 10.462% more volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.
-
Which is a Better Dividend Stock SDMHF or IVA?
Sartorius Stedim Biotech SA has a quarterly dividend of $0.74 per share corresponding to a yield of 0.3%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius Stedim Biotech SA pays 38.14% of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend. Sartorius Stedim Biotech SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SDMHF or IVA?
Sartorius Stedim Biotech SA quarterly revenues are $824.6M, which are larger than Inventiva SA quarterly revenues of --. Sartorius Stedim Biotech SA's net income of $75.6M is higher than Inventiva SA's net income of --. Notably, Sartorius Stedim Biotech SA's price-to-earnings ratio is 82.54x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius Stedim Biotech SA is 7.39x versus 24.04x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDMHFSartorius Stedim Biotech SA7.39x 82.54x $824.6M $75.6M IVAInventiva SA24.04x -- -- --
-
Which has Higher Returns SDMHF or NBTX?
Nanobiotix SA has a net margin of 9.17% compared to Sartorius Stedim Biotech SA's net margin of --. Sartorius Stedim Biotech SA's return on equity of 6.53% beat Nanobiotix SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SDMHFSartorius Stedim Biotech SA46.39% $0.77 $7.8B NBTXNanobiotix SA-- -- $24.3M -
What do Analysts Say About SDMHF or NBTX?
Sartorius Stedim Biotech SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nanobiotix SA has an analysts' consensus of $14.75 which suggests that it could fall by -30.25%. Given that Nanobiotix SA has higher upside potential than Sartorius Stedim Biotech SA, analysts believe Nanobiotix SA is more attractive than Sartorius Stedim Biotech SA.
Company Buy Ratings Hold Ratings Sell Ratings SDMHFSartorius Stedim Biotech SA0 0 0 NBTXNanobiotix SA4 1 0 -
Is SDMHF or NBTX More Risky?
Sartorius Stedim Biotech SA has a beta of 1.105, which suggesting that the stock is 10.462% more volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SDMHF or NBTX?
Sartorius Stedim Biotech SA has a quarterly dividend of $0.74 per share corresponding to a yield of 0.3%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius Stedim Biotech SA pays 38.14% of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend. Sartorius Stedim Biotech SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SDMHF or NBTX?
Sartorius Stedim Biotech SA quarterly revenues are $824.6M, which are larger than Nanobiotix SA quarterly revenues of --. Sartorius Stedim Biotech SA's net income of $75.6M is higher than Nanobiotix SA's net income of --. Notably, Sartorius Stedim Biotech SA's price-to-earnings ratio is 82.54x while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius Stedim Biotech SA is 7.39x versus 29.50x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDMHFSartorius Stedim Biotech SA7.39x 82.54x $824.6M $75.6M NBTXNanobiotix SA29.50x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 31.68% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 45.78% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.15% over the past day.
